肿瘤浸润淋巴细胞对非小细胞肺癌预后的影响：系统评价和荟萃分析。
Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis.
机构信息
Department of Head and Neck Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
出版信息
Front Immunol. 2024 Sep 20;15:1476365. doi: 10.3389/fimmu.2024.1476365. eCollection 2024.
BACKGROUND
Tumor-infiltrating lymphocytes (TILs) have demonstrated potential as prognostic biomarkers across various cancer types. However, their prognostic implications in non-small cell lung cancer (NSCLC) remain ambiguous.
METHODS
An exhaustive electronic search was executed across the Pubmed, EMBASE, Web of Science, and Cochrane Library databases to locate relevant studies published up until December 19, 2023. Studies were eligible if they assessed the association between TILs and overall survival (OS) and disease-free survival (DFS) in NSCLC patients. The OS and DFS were subsequently extracted for analysis. The prognostic significance of TILs was evaluated by calculating the Pooled Hazard Ratios (HRs) and their corresponding 95% Confidence Intervals (CIs).
RESULTS
The meta-analysis incorporated 60 studies, which collectively included 15829 NSCLC patients. The collective analysis indicated that NSCLC patients exhibiting TILs infiltration demonstrated a significantly improved OS(HR: 0.67; 95%CI: 0.55-0.81). Subgroup analyses, based on TIL subtypes (CD8+, CD3+ and CD4+), consistently revealed a favorable prognostic impact on OS. However, it was observed that FOXP3+ was correlated with a poor OS (HR: 1.35; 95% CI: 0.87-2.11).
CONCLUSION
This comprehensive systematic review and meta-analysis substantiate the prognostic significance of TILs in patients diagnosed with NSCLC. Notably, elevated TILs infiltration correlates with a favorable prognosis, particularly among CD8+, CD3+ and CD4+ subtypes.
SYSTEMATIC REVIEW REGISTRATION
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023468089 PROSPERO, identifier CRD42023468089.
背景
肿瘤浸润淋巴细胞（TILs）已被证明在多种癌症类型中具有作为预后生物标志物的潜力。然而，它们在非小细胞肺癌（NSCLC）中的预后意义仍不明确。
方法
通过对 Pubmed、EMBASE、Web of Science 和 Cochrane Library 数据库进行全面的电子检索，查找截至 2023 年 12 月 19 日发表的相关研究。如果研究评估了 TILs 与 NSCLC 患者的总生存期（OS）和无病生存期（DFS）之间的关联，则符合纳入标准。随后提取 OS 和 DFS 进行分析。通过计算合并风险比（HRs）及其相应的 95%置信区间（CIs）来评估 TILs 的预后意义。
结果
该荟萃分析纳入了 60 项研究，共纳入了 15829 例 NSCLC 患者。综合分析表明，TILs 浸润的 NSCLC 患者 OS 显著改善（HR：0.67；95%CI：0.55-0.81）。基于 TIL 亚型（CD8+、CD3+和 CD4+）的亚组分析一致显示对 OS 有有利的预后影响。然而，观察到 FOXP3+与 OS 不良相关（HR：1.35；95%CI：0.87-2.11）。
结论
这项全面的系统评价和荟萃分析证实了 TILs 在诊断为 NSCLC 的患者中的预后意义。值得注意的是，TILs 浸润增加与预后良好相关，特别是在 CD8+、CD3+和 CD4+亚型中。
系统评价注册
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023468089 PROSPERO，标识符 CRD42023468089。
Zotero 插件